TNF Inhibition for Ophthalmic Indications: Current Status and Outlook

@article{Rifkin2013TNFIF,
  title={TNF Inhibition for Ophthalmic Indications: Current Status and Outlook},
  author={Lana M. Rifkin and Andrea D. Birnbaum and Debra Anne Goldstein},
  journal={BioDrugs},
  year={2013},
  volume={27},
  pages={347-357}
}
BackgroundTumor necrosis factors (TNF) are a group of cytokines that play a role in systemic inflammation, stimulating the acute phase reaction. They are involved in systemic rheumatologic conditions such as rheumatoid arthritis and juvenile idiopathic arthritis, as well as ocular inflammatory conditions in the uveitis spectrum. Several drugs were developed to inhibit the action of TNF, thereby reducing inflammation. The three most commonly used TNF inhibitors in the US are etanercept… Expand
Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis
TLDR
This review aims to provide an updated report on the efficacy of biologics that target TNF-α,IL-1β, IL-6, and IL-17 for the treatment of autoimmune uveitis. Expand
Paradoxical effects of anti-TNF-α agents in inflammatory diseases
TLDR
The so-called paradoxical effects of anti-TNF agents represent new onset or exacerbation of a condition (symptom/disease), usually improved with TNF blockers, and may raise differential diagnosis problems. Expand
Tumor necrosis factor inhibitors – state of knowledge
TLDR
The background and place for TNF inhibitors in modern therapy are discussed, and the main safety aspects of TNF inhibitor administration are described in particular, with special consideration of the available meta-analyses. Expand
Therapeutic targets for rheumatoid arthritis: Progress and promises
TLDR
Current evidences suggest that multiligand receptor for advanced glycation end products (RAGE), several adipokines and various components of immune system play a critical role in the pathophysiology of RA; therefore, they are highlighted as therapeutic targets for RA therapy. Expand
Adalimumab in the treatment of non-infectious uveitis.
TLDR
The standard treatment for NIU is a local, topical and systemic steroid therapy in combination with immunomodulatory therapy, but recently, a new drug - adalimumab, which is a tumor necrosis factor α (TNF-α) inhibitor - was approved by FDA in the treatment of NIU and is increasingly used to treat various conditions. Expand
Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
TLDR
It is demonstrated that adalimumab is a very effective and safe option for treatment of patients with severe and resistant Behçet's uveitis, providing an appropriate and long-term control of ocular inflammation. Expand
An anti-TNF-α antibody mimetic to treat ocular inflammation
TLDR
Both Infliximab and FpFinNetfliximab suppressed ocular inflammation by reducing the number of CD45+ infiltrate cells in the EAU mice after a single intravitreal injection at the onset of peak disease. Expand
Practical Guide to Immunomodulatory Agents
TLDR
Because peripheral ulcerative keratitis especially in the presence of necrotizing scleritis is associated with significant risk of mortality, initiation of systemic immunomodulatory therapy can be not only sight-saving but life-saving, as well. Expand
Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.
TLDR
3 cases of uveal melanocytic tumors occurring after the use of TNF-α inhibitors add to the growing literature suggesting a correlation between TNF -α inhibitors and the development of malignant neoplasms. Expand
Tumor Necrosis Factor-&agr; Inhibitors as a Treatment of Corneal Hemangiogenesis and Lymphangiogenesis
TLDR
The role of TNF-&agr; on the ocular surface and, in particular, its specific role in the process of CNV is reviewed. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 91 REFERENCES
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
TLDR
TNF inhibitors are well tolerated immunosuppressive medications that may benefit certain subgroups of patients with inflammatory eye disease, but they appear to be more effective in controlling associated inflammatory arthritis. Expand
Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
TLDR
Infliximab was more effective than etanercept in the treatment of recalcitrant uveitis and decreased the use of topical steroids. Expand
New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
TLDR
Uveitis occurs de novo under anti-TNF therapy mainly in spondyloarthropathies, but also in rheumatoid arthritis and juvenile idiopathic arthritis patients and more frequently under etanercept. Expand
Drug therapy of inflammatory arthritis.
TLDR
The use of biologic therapies has increased dramatically across a range of indications and has resulted in improved outcomes for patients, but these agents are associated with an increased risk of infection, particularly tuberculosis in patients receiving tumour necrosis factor inhibitors. Expand
Golimumab for uveitis.
TLDR
Golimumab (GLM), a fully human anti-TNF monoclonal antibody, was approved by the US Food and Drug Administration in 2009 for the use with methotrexate (MTX) in adults with moderate to severe active RA, and with or without MTX or other biologic disease-modifying anti-rheumatic drugs in Adults with active PsA or active AS. Expand
Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial
TLDR
Adalimumab was safe and effective in 68% of refractory uveitis patients 10 weeks after study enrolment, and maintained in 39% after 1 year, and Ongoing study is required to determine the place of adAlimumab and other TNF blockers in the treatment of uveritis. Expand
Optic Neuritis Associated with Adalimumab in the Treatment of Uveitis
TLDR
A case of optic neuritis and multiple sclerosis developing in association with the use of adalimumab for the treatment of bilateral chronic granulomatous iridocyclitis and multifocal choroiditis is reported, demonstrating the strong association between TNF inhibitors and CNS demyelination. Expand
Favorable response to high-dose infliximab for refractory childhood uveitis.
TLDR
High-dose infliximab was a rapidly effective, well-tolerated therapeutic agent for the treatment of chronic, medically refractory, noninfectious uveitis. Expand
A PEGylated Fab’ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease
TLDR
The property identified that reflected the efficacies of the anti-TNFα agents etanercept, adalimumab, certolizumab pegol, and infliximab in CD was the ability to inhibit the cytokine production by monocytes that is induced by bacterial lipopolysaccharide, suggesting that this mode of action is important for efficacy in CD. Expand
Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis
TLDR
Infliximab seems to be an effective and safe treatment for noninfectious uveitis and scleritis and may be indicated as rescue therapy for relapses of ocular inflammation or as maintenance therapy when conventional immunosuppression has failed. Expand
...
1
2
3
4
5
...